alexa
Reach Us +1-218-451-2974
Richard Meibach | OMICS International
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

14th International Conference on Alzheimer s Disease & Dementia

Zurich, Switzerland

12th World Congress on Alzheimers Disease & Dementia

Budapest, Hungary
Share This Page

Richard Meibach

Hoffmann-La Roche Inc., Pharmaceuticals

Biography

Dr . Richard C. Meibach, Ph.D., is currently the Global Head of Regulatory Affairs for Neuroscience and Ophthalmology at Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Meibach had been Vice President of Clinical Science at Hoffmann-La Roche Inc., Pharmaceuticals. For 10 years he had global responsibility for central and peripheral nervous system diseases, and urology. He received his Ph.D. in biomedical sciences from the Graduate School of Biomedical Sciences, New Jersey Medical School (1976). Dr. Meibach did a 2-year postdoctoral fellowship in neurology at Albert Einstein College of Medicine, New York. In 1978, he became an assistant professor of pharmacology at Mount Sinai School of Medicine in New York. His research interests were in the anatomical and functional connections of the limbic and extrapyramidal systems in the brain. Major discoveries included the determination of the origin of the fornix system, localization and visualization of serotoninergic type 2 receptors in the brain, and the localization of phencylclidine (angel dust) effects on brain metabolism. Dr. Meibach left basic academic research in 1983 to pursue a clinical research career in the pharmaceutical industry.

 

Research Interest

 His research interests were in the anatomical and functional connections of the limbic and extrapyramidal systems in the brain. Major discoveries included the determination of the origin of the fornix system, localization and visualization of serotoninergic type 2 receptors in the brain, and the localization of phencylclidine (angel dust) effects on brain metabolism.

Publications
Top